Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Weekend | Pharma | 10.1% | 37th pct | 110 |
| Helios Pharma | Pharma | -24.5% | 2nd pct | 110 |
| New Medi | Pharma | — | no FY data | 110 |
| Medi-Hels | Pharma | — | no FY data | 110 |
| Deilait Kompani | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 5 peers filed FY2024. Switch to FY2021 (5 of 5).
| Ratio — FY 2024 | Helios Pharma | Weekend | New Medi | Medi-Hels | Deilait Kompani |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 76.8% | 47.0% | — | — | — |
| EBITDA Margin | -24.5% | 10.1% | — | — | — |
| EBITDAR | -123 | 47 | — | — | — |
| EBITDAR Margin | -19.1% | 13.8% | — | — | — |
| EBIT Margin | -24.9% | 10.1% | — | — | — |
| Net Profit Margin | 11.1% | 10.1% | — | — | — |
| Operating Expense % of Sales | 101.3% | 36.9% | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | 0.6% | 0.3% | — | — | — |
| Return on Equity (ROE) | 0.6% | 0.4% | — | — | — |
| ROIC [EBIT / Invested Capital] | -1.4% | 0.4% | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 30.6% | — | — | — |
| Debt-to-Equity | 0.00x | 0.46x | — | — | — |
| Debt-to-EBITDA | N/A | 107.38x | — | — | — |
| Equity-to-Assets | 99.2% | 65.9% | — | — | — |
| Net Debt | -853 | 1,332 | — | — | — |
| Cash & Equivalents | 853 | 2,418 | — | — | — |
| Total Debt | N/A | 3,750 | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | N/A | 1.50x | — | — | — |
| Quick Ratio | N/A | 1.18x | — | — | — |
| Cash Ratio | N/A | 0.50x | — | — | — |
| Total Current Assets | 12,305 | 7,291 | — | — | — |
| Total Current Liabilities | N/A | 4,873 | — | — | — |
| Inventory | N/A | 1,557 | — | — | — |
| Trade Receivables | 949 | 3,316 | — | — | — |
| Trade Payables | N/A | 431 | — | — | — |
| Net Working Capital | 12,305 | 2,418 | — | — | — |
| Net Working Capital % of Revenue | 1906.8% | 701.7% | — | — | — |
| Trade Working Capital | 949 | 4,442 | — | — | — |
| Trade Working Capital % of Revenue | 147.1% | 1289.1% | — | — | — |
| Change in Trade Working Capital | N/A | N/A | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 0.12x | — | — | — |
| Days Inventory Outstanding (DIO) | N/A | 3112.5 | — | — | — |
| Receivables Turnover | 0.68x | 0.10x | — | — | — |
| Days Sales Outstanding (DSO) | 537.0 | 3512.4 | — | — | — |
| Payables Turnover | N/A | 0.42x | — | — | — |
| Days Payable Outstanding (DPO) | N/A | 860.8 | — | — | — |
| Cash Conversion Cycle | 537.0 days | 5764.1 days | — | — | — |
| Asset Turnover | 0.05x | 0.03x | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 2,282 | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | N/A | 10 | — | — | — |
| Cash Conversion (OCF / EBITDA) | N/A | 6533.8% | — | — | — |
| Dividends Declared | N/A | 0 | — | — | — |
| Dividend Payout Ratio | N/A | 0.0% | — | — | — |